META:PHI in Primary Care: Implementing Best Practices for Addictions

1. META:PHI in Primary Care: Implementing Best Practices for Addictions Safe Opioid Prescribing

2. What is META:PHI? Mentoring, Education, and Clinical Tools for Addiction: Primary Care–Hospital Integration Collaborative project to implement integrated care pathways for addiction throughout Ontario Partnership between hospitals, withdrawal management services, FHTs, CHCs, and community agencies Goals: Improve care for patients with addictions Improve care provider experience Improve population health Reduce service use Provide sustainable care

3. How it works Patients presenting with addiction-related concerns receive evidence-based interventions and are referred to rapid access addiction medicine (RAAM) clinics for treatment RAAM clinics offer substance use disorder treatment on walk-in basis; no formal referral/appointment needed Patients stabilized at RAAM clinic referred back to primary care for long-term addiction treatment (with ongoing support from RAAM clinic as required) Key components: Integration of care at hospital, RAAM clinic, primary care Training, support, and mentorship from addictions specialists Capacity-building

4. Role of PCPs With support from META:PHI team: Follow best practices for prescribing opioids Screen and diagnose patients for substance use disorders Refer patients to treatment at RAAM clinic when necessary Take over long-term addiction care for patients (with ongoing support from RAAM clinic doctor)

5. Practice goals for managing patients’ opioid use

6. Practice goals Only prescribe to patients for whom opioids are likely to be safe and effective. Always begin therapy with weak opioids. When prescribing potent opioids, start with a low dose and titrate slowly. Routinely monitor patients on opioid medications to ensure that they are experiencing meaningful benefit. Provide patients with education on safely storing medication, preventing overdose, and the risks of sharing opioids with others. Initiate appropriate treatment or facilitate referral for patients with an opioid use disorder.

7. Opioids for acute pain

8. Opioid treatment for acute pain Indications Moderate to severe pain that has not responded to an adequate trial of evidence-based non-opioid treatments (acetaminophen, SNRIs, NSAIDs, physiotherapy) Contraindications Mild pain (e.g., low pack pain, dental pain, muscle strains) Active substance use disorder

9. Protocol for prescribing Use lowest effective dose Immediate-release formulation, ideally combined with a non-opioid medication (e.g., codeine + acetaminophen) Prescribe only enough to last for expected duration of severe pain Usually 3 days or less Never more than 7 days

10. Initiating opioid therapy for chronic non-cancer pain

11. Considering an opioid trial Indications: Patient has well-defined pain condition (nociceptive or neuropathic) that… Has been shown to respond to opioids Causes both pain and disability Non-opioid treatments are ineffective, contraindicated, or have intolerable side effects Precautions: Patient has current, active psychiatric disorder Contraindications: Patient has current, recent, or severe past history of substance use disorder (alcohol, opioids, cannabis, etc.)

12. Prior to prescribing opioids (1) Ask about current/past use of alcohol and drugs Ask about mood Patients with depression tend to have heightened perception of pain and may be less responsive to opioids Check renal/respiratory status, especially risk of sleep apnea Assess risk of falls Consider tapering benzodiazepines Ask about impact of pain on activities of daily living Rate pain on 0–10 scale (at rest and with activity)

13. Prior to prescribing opioids (2) Reassess response to non-opioid treatments: Nociceptive pain: acetaminophen, NSAIDs, SNRIs Neuropathic pain: anticonvulsants, SNRIs, TCAs All pain: Mindfulness programs, graded exercise Inform patient that opioid therapy will be a trial, to be discontinued if side effects outweigh benefits Advise patients not to drink alcohol during titration Warn patients to avoid driving for at least two hours after a dose in the first 1–2 weeks of treatment initiation and the first week of dose increase Warn patients to keep their opioids securely stored and not to give any to anyone else

14. Office visits See patient frequently during initiation and titration At each visit, ask about changes in: Work, school, social activities, daily activities Pain ratings (0–10) at rest and with activity Mood Ask about side effects Sedation, dizziness, other CNS effects Constipation, nausea

15. Prescribing protocol

16. IR vs. CR Initiate opioid trial with IR preparations Maintain on IR for brief (< 4 hours) or incident pain For constant pain throughout the day, switch to CR In long-term therapy for constant pain throughout the day, IR medications for breakthrough pain should not exceed 10–30% of total daily dose

17. Opioid selection Initiate with weak opioids: oral codeine, tramadol, or buprenorphine patch If insufficient analgesia, switch to morphine, oxycodone, or hydromorphone Morphine contraindicated in patients with renal insufficiency Some evidence that hydromorphone and oxycodone have fewer cognitive effects in the elderly than morphine Use extreme caution when prescribing transdermal fentanyl Contraindicated in elderly patients and patients at risk for opioid use disorder Use only if patient has taken at least 60–100 mg MEQ daily for at least 2 weeks

18. Initiation and titration *Maximum CR dose 250 mg bid. Exert caution when switching from pure mu-opioids.

19. Morphine equivalency

20. Optimal dose Effective opioid therapy causes gradual improvement in pain/function as dose increases Optimal dose reached if: Pain relief at least 2 points on 10-point scale, with no additional benefit from 1–2 additional increases Improved functioning at work, school, and with family; increased physical activities No major side effects Most patients respond to a dose of 50 mg MEQ or less Doses above 90 mg MEQ are rarely needed

21. Ongoing vigilance Opioids have dose-related complications (overdose, sleep apnea, falls/fractures, etc.) Patients with ongoing prescriptions of 40 mg MEQ or more should have monthly visits to asses: Pain levels (at rest and with activity) Function (mood, activities of daily living) Adverse effects At doses of 90+ mg MEQ, reassess analgesic effectiveness and side effects Consider tapering for patients who are receiving insufficient analgesia and/or suffering from opioid-related complications

22. Minimizing adverse effects of opioid therapy

23. Patients at risk of falls Do not prescribe opioids to cognitively impaired patients unless dispensed and overseen by caregiver Taper benzodiazepines Benzodiazepines increase risk and severity of opioid-induced fatigue, sedation, inattention, and overdose Avoid use of opioids at night if possible If pain wakes patient up, prescribe small IR dose and warn patient to take extra precautions when getting out of bed

24. Sedation during initiation or dose increase Inform patient and family of signs of impending overdose Sedation, slowed speech, nodding off Patient may appear relatively alert in conversation but have respiratory arrest at night while asleep Family members should call emergency services at the first sign of an overdose

25. Fatigue Opioids can cause fatigue either through direct sedating effect or contributing to sleep apnea If patient reports daytime fatigue or reduced function: Assess for sleep apnea Consider reducing or switching opioid

26. Constipation Increase fibre, fluid, activity Consider laxatives: Polyethylene glycol most effective for opioid-induced constipation Sodium picosulphate or lactulose may also be effective

27. Opioid switching and tapering

28. Indications for switching Inadequate analgesic response (pain relief < 2/10, no improvement in function) to current opioid despite reasonable dose Adverse effects with current opioid (e.g., constipation, sedation)

29. Switching protocol Start with 50% of MEQ of original opioid Patient will not be fully tolerant to new opioid Example: When switching a patient from 40 mg/d of oxycodone to hydromorphone… 40 mg/d oxycodone = 60 mg MEQ 60 mg MEQ = 12 mg/d hydromorphone 50% of hydromorphone 12 mg = 6 mg Therefore, start patient on 6 mg/d in divided doses Tell patient that taking extra doses is dangerous

30. Why taper? Tapering after a failed opioid trial often improves patient’s pain, mood, and functioning Abrupt cessation is very dangerous Will trigger severe withdrawal Patient will lose tolerance, increasing risk of overdose Patient may seek illicit sources of opioids to relieve their withdrawal symptoms (danger of accidental exposure to fentanyl)

31. Indications for tapering Patient has persistent severe pain and pain-related disability despite adequate dose, and has already failed on a trial of at least one opioid previously Patient is on an unusually high dose for pain condition Patient has a complication from opioid therapy Patient has suspected opioid use disorder, and opioid maintenance therapy with methadone or buprenorphine/ naloxone is not an option

32. Reluctance to taper Patient may worry that tapering will make their pain worse Explain why you are tapering: “I am lowering your opioid dose to prevent future harms and improve your mood and well-being.” “Tapering is actually likely to improve your pain; opioids often stop working after many months or years, and they can lower your pain threshold, making your pain worse.” “We’re not necessarily going to stop your opioid; we’re going to lower it to a dose thatimproves your mood and functioning whilekeeping your pain manageable.” “We’ll do this gradually, and I’ll keep checking in to see how you’re doing.”

33. Tapering protocol

34. Problematic Opioid use

35. Limiting diversion Tell patients to store their medication in a locked box or other secure location Tell patients not to share their medication with anyone Avoid using fentanyl patches in elderly patients with younger adults at home (patches can be easily lifted off a sleeping patient)

36. Monitoring for problematic use Any patient with an ongoing prescription of 40 mg MEQ or more should be monitored for signs of problematic use At each visit, ask the patient about: Changes in mood, relationships, functioning Concerns expressed by family/friends Unauthorized changes to dose, schedule (i.e., binge use), or route of delivery (e.g., biting oral tablets) Euphoric effects immediately after taking a dose Withdrawal symptoms Drug-seeking behaviours: running out of medication early, frequent requests for dose increases, etc. These features may indicate that the patient is at risk for an opioid use disorder

37. Wrap-up: Key Messages

38. Our responsibility Prescribing opioids safely for patients suffering from chronic non-cancer pain is our responsibility as health care providers Addiction can occur as a complication of opioid therapy As prescribers, we need to be able to recognize the signs of addiction and know how to intervene Effective addiction treatments are available Purpose of META:PHI project is to facilitate adoption of best practices and support clinicians

39. Resources META:PHI website: www.metaphi.ca META:PHI mailing list for clinical questions and discussion (e-mail sarah.clarke@wchospital.ca to join) META:PHI contacts:Medical lead: Dr. Meldon Kahan meldon.kahan@wchospital.ca Manager: Kate Hardykate.hardy@wchospital.ca Knowledge broker: Sarah Clarke sarah.clarke@wchospital.ca